Patents by Inventor Karen Y. Twu

Karen Y. Twu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Development of influenza A antivirals
    Patent number: 9499595
    Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: November 22, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS
    Inventors: Robert M. Krug, Karen Y. Twu
  • Influenza A virus vaccines and inhibitors
    Patent number: 9079944
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: July 14, 2015
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Influenza A Virus Vaccines and Inhibitors
    Publication number: 20150093405
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Application
    Filed: November 17, 2014
    Publication date: April 2, 2015
    Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Influenza A virus vaccines and inhibitors
    Patent number: 8916519
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 23, 2014
    Assignees: Rutgers, The State University of New Jersey, Board of Regents, The University of Texas System
    Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Influenza A Virus Vaccines and Inhibitors
    Publication number: 20140308307
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Influenza A virus vaccines and inhibitors
    Patent number: 8796008
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF 30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: August 5, 2014
    Assignees: Board of Regents, The University of Texas System, Rutgers, The State University of New Jersey
    Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Rei-Lin Kuo, Robert M. Krug, Karen Y. Twu
  • Influenza A Virus Vaccines and Inhibitors
    Publication number: 20140044745
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Application
    Filed: May 31, 2013
    Publication date: February 13, 2014
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Influenza A virus vaccines and inhibitors
    Patent number: 8455621
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: June 4, 2013
    Assignees: Rutgers, The State University of New Jersery, Board of Regents, The University of Texas System
    Inventors: Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo, Gaetano Montelione, Edward Arnold, Kalyan Das, LiChung Ma, Rong Xiao
  • Influenza A Virus Vaccines and Inhibitors
    Publication number: 20100247569
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Application
    Filed: February 17, 2010
    Publication date: September 30, 2010
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • Influenza A virus vaccines and inhibitors
    Patent number: 7709190
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Grant
    Filed: December 2, 2006
    Date of Patent: May 4, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
  • DEVELOPMENT OF INFLUENZA A ANTIVIRALS
    Publication number: 20100107264
    Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.
    Type: Application
    Filed: September 4, 2009
    Publication date: April 29, 2010
    Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert M. Krug, Karen Y. Twu
  • Development of influenza A antivirals
    Patent number: 7601490
    Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.
    Type: Grant
    Filed: December 2, 2006
    Date of Patent: October 13, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert M. Krug, Karen Y. Twu
  • INFLUENZA A VIRUS VACCINES AND INHIBITORS
    Publication number: 20080108050
    Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
    Type: Application
    Filed: December 2, 2006
    Publication date: May 8, 2008
    Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo